These data suggest that a B cell-specific conditional Tp53 deletion, for instance through the use of Cd19-CreERT2 deleter mice on the Eμ-Tcl1 background, might be a useful experimental strategy to faithfully mimic clonal evolution of p53-defective CLL. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.